

BRIEF DEFINITIVE REPORT

SPRED1 deletion confers resistance to MAPK inhibition in melanoma

Julien Ablain¹, Sixue Liu^{2,4}, Gatien Moriceau^{2,4,5}, Roger S. Lo^{2,3,4,5}, and Leonard I. Zon^{1,6,7}

Functional evaluation of genetic lesions can discover a role in cancer initiation and progression and help develop novel therapeutic strategies. We previously identified the negative MAPK regulator *SPRED1* as a novel tumor suppressor in KIT-driven melanoma. Here, we show that *SPRED1* is also frequently deleted in human melanoma driven by mutant BRAF. We found that *SPRED1* inactivation in human melanoma cell lines and primary zebrafish melanoma conferred resistance to BRAF^{V600E} inhibition in vitro and in vivo. Mechanistically, *SPRED1* loss promoted melanoma cell proliferation under mutant BRAF inhibition by reactivating MAPK activity. Consistently, biallelic deletion of *SPRED1* was observed in a patient whose melanoma acquired resistance to MAPK-targeted therapy. These studies combining work in human cells and in vivo modeling in zebrafish demonstrate a new mechanism of resistance to BRAF^{V600E} inhibition in melanoma.

Introduction

Next-generation sequencing of human tumors performed by The Cancer Genome Atlas (TCGA) Research Network has uncovered a plethora of genomic abnormalities that may be used to identify potential novel oncogenes or tumor suppressors (McLendon et al., 2008). Most functional analyses have focused on recurrent point mutations, but the role of copy-number alterations remains understudied. Functional assessment of amplified or deleted chromosomal regions is necessary to formally implicate candidate genes in malignant processes and discover new therapeutically actionable cancer vulnerabilities.

Melanoma is one of the tumor types exhibiting the most genetic alterations (Alexandrov et al., 2013). Its formation is fueled by the hyperactivation of the MAPK pathway through activating mutations in genes like *BRAF*, *NRAS*, and *KIT* or via the inactivation of negative regulators of the pathway, such as *NF1* (Akbani et al., 2015; Hayward et al., 2017). Close to 50% of cutaneous melanoma are driven by the BRAF^{V600E} mutant, and specific BRAF^{V600E} inhibitors have shown remarkable clinical efficacy (Bollag et al., 2010; Flaherty et al., 2010; Chapman et al., 2011; Hauschild et al., 2012). However, resistance to these targeted therapies invariably arises within a year of treatment start (Chapman et al., 2011; McArthur et al., 2014; Wagle et al., 2011). In most cases, resistance is due to the reactivation of the MAPK pathway through additional genomic lesions affecting *BRAF* itself

or other players of the pathway (Wagle et al., 2011; Johannessen et al., 2010; Nazarian et al., 2010; Shi et al., 2012).

By analyzing copy-number alterations in human melanoma, we recently identified frequent biallelic deletions of *SPRED1* (Sprouty-related Ena/VASP homology 1 [EVH1] domain containing 1; Ablain et al., 2018). *SPRED1* is a negative regulator of the MAPK pathway (Nonami et al., 2004; Wakioka et al., 2001). In humans, inactivating germline mutations in *SPRED1* cause Legius syndrome, a developmental disorder characterized by skin pigmentation abnormalities reminiscent of neurofibromatosis type 1 (Hirata et al., 2016; Brems et al., 2007). Neurofibromatosis type 1 is due to the loss of function of the neurofibromin (*NF1*) gene that encodes a GTPase (guanosine triphosphatase)-activating protein that catalyzes the conversion of active GTP-bound Ras into inactive guanosine diphosphate-bound Ras, resulting in the down-regulation of the MAPK pathway (Xu et al., 1990a, b; Ballester et al., 1990; Martin et al., 1990). The similarities between Legius syndrome and neurofibromatosis type 1 suggested that *SPRED1* and *NF1* share biological functions. Indeed, at the molecular level, *SPRED1* has been shown to directly recruit *NF1* to the plasma membrane, thus allowing it to inhibit Ras activity (Stowe et al., 2012). Structural insights have recently confirmed the physical interactions between *SPRED1*, *NF1*, and Ras (Yan et al., 2020). We previously demonstrated

¹Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana Farber Cancer Institute, Boston, MA; ²Division of Dermatology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA; ³Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA; ⁴David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA; ⁵Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA; ⁶Harvard Stem Cell Institute, Harvard University, Cambridge, MA; ⁷Howard Hughes Medical Institute, Boston, MA.

Correspondence to Leonard I. Zon: zon@enders.tch.harvard.edu.

© 2020 Ablain et al. This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see <http://www.rupress.org/terms/>). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 4.0 International license, as described at <https://creativecommons.org/licenses/by-nc-sa/4.0/>).

that *SPRED1* acts as a tumor-suppressor gene in melanoma, especially in the context of *KIT* mutations (Ablain et al., 2018).

Here, we report that *SPRED1* deletions can also be found in melanoma driven by *BRAF* mutants. Modeling *SPRED1* loss in adult zebrafish melanoma and human melanoma cell lines, we show that it confers resistance to *BRAF* inhibition by sustaining low levels of MAPK signaling. We also found *SPRED1* deletions associated with acquired resistance to MAPK inhibition in a patient with melanoma. Our data thus nominate *SPRED1* loss as a new mechanism of resistance to MAPK-targeted therapy in melanoma.

Results and discussion

SPRED1 is frequently deleted in human cutaneous melanoma

SPRED1 is the only gene found in a frequent focal deletion on chromosome 15 (chr15:38,244,770–38,745,783; overall frequency, 24%; q-value = 0.0076) identified by GISTIC analysis of a cohort of 363 human cutaneous melanoma samples with both copy-number and mutation information from the Pan-Cancer TCGA dataset (Fig. 1 A). Overall, *SPRED1* was altered in 22 of 363 cases (6%). Homozygous deletions were present in 10 patients with cutaneous melanoma (2.7%), while 4 and 7 of 363 cases (1.1% and 1.9%) harbored truncating mutations and missense mutations, respectively (Fig. 1 B). A gene fusion that likely acts as a truncating event was also detected in one patient. We can thus estimate *SPRED1* loss-of-function alterations at 4.1% of human cutaneous melanomas. Note that some point mutations may also result in loss of function, especially those affecting the EVH1 and Sprouty-related regions, the functional domains of *SPRED1*.

SPRED1 is also homozygously deleted in 5% of mesothelioma (4 of 82 cases) and 3% of ovarian cancer (12 of 398 cases). It is inactivated in 4% of lung adenocarcinoma (19 of 507 cases), mostly through deep deletions and truncating mutations, similar to melanoma and consistent with the critical role of the MAPK pathway as an oncogenic driver of this tumor type. In addition, *SPRED1* is altered in 7% of uterine corpus endometrial carcinoma (34 of 509 cases). In this tumor type, *SPRED1* alterations are mostly missense or truncating mutations, thus differing from the pattern observed in melanoma. However, these alterations significantly co-occur with *NF1* loss of function as well as with receptor tyrosine kinase mutations (in *KIT* or *EGFR*), suggesting that a subtype of uterine cancers is driven by MAPK activation.

Importantly, low *SPRED1* expression correlates with poor prognosis in patients with melanoma (Fig. 1 C). Among the samples with *SPRED1* alterations, genetic lesions in *CDKN2A* and *TP53* accounted for the majority of tumor-suppressor losses (Fig. S1 A). While *KIT* mutations or amplifications were frequent, as previously noted (Ablain et al., 2018), 13 out of 22 melanoma samples with *SPRED1* alterations exhibited *BRAF* mutations (Fig. 1 B). These genomic data indicate that *SPRED1* is recurrently lost in *BRAF*-driven human melanoma, prompting us to test its role by genetic manipulation in human melanoma cell lines and zebrafish models.

SPRED1 inactivation modestly alters melanoma growth in vitro and in vivo

We first investigated the effects of *SPRED1* loss on melanoma growth. We selected two efficient shRNAs against *SPRED1* (sh#2

and sh#4; Fig. S1 B) and observed that *SPRED1* down-regulation did not affect cell proliferation in *BRAF*^{V600E}-driven human melanoma cell lines (Fig. S1 C). To test the role of *SPRED1* in melanoma in vivo, we inactivated *spred1* by CRISPR in a *BRAF*-driven zebrafish melanoma model using a method that we developed previously (Ablain et al., 2015, 2018; Ceol et al., 2011). This only slightly, but not significantly, affected tumor onset in conjunction with *tp53* loss (Fig. S1 D), even though 70% of tumors displayed inactivating indels at *spred1* CRISPR target locus, as assessed by deep sequencing (Fig. S1 E). Yet, *spred1* inactivation accelerated melanoma onset in the context of *cdkn2a* loss that yields less aggressive tumors in zebrafish (Fig. S1 F). These in vivo data support the existence of a selective pressure for *SPRED1* loss, consistent with our analyses of human melanoma genetics. Overall, these results indicate that *SPRED1* loss modestly increases melanoma initiation and proliferation in the background of *BRAF* activating mutations.

Interestingly, we noticed that four of the *BRAF* mutations cooccurring with *SPRED1* alterations did not affect the V600 residue that concentrates 80% of *BRAF* mutations in melanoma (Fig. 1 B). Three of them (G466E, S467L, and G469E) are known as class 3 *BRAF* mutants (Yao et al., 2017). Unlike *BRAF*^{V600E}, which exhibits enhanced kinase activity and acts as a monomer, class 3 *BRAF* mutants display low kinase activity but increased binding to wild-type Ras and CRAF, which results in MAPK pathway activation. This genetic observation raises the intriguing possibility that the effects of *SPRED1* loss of function on melanoma growth may be more evident in the context of weaker oncogenic drivers that act through the wild-type Ras/RAF pathway.

SPRED1 down-regulation reduces sensitivity to *BRAF* inhibition in *BRAF*-driven human melanoma cell lines by sustaining MAPK activity

Because of the functional similarities between *NF1* and *SPRED1* and the fact that *NF1* loss confers resistance to *BRAF* inhibition in *BRAF* mutant melanoma (Whittaker et al., 2013; Maertens et al., 2013), we examined the impact of *SPRED1* loss on oncogene inhibition. *SPRED1* down-regulation significantly decreased sensitivity to the *BRAF*^{V600E} inhibitor dabrafenib, as assessed by cell viability over a range of drug concentrations in two different *BRAF*-driven melanoma cell lines, A375 and UACC257 (Fig. 2 A and Fig. S2 A). *SPRED1* inactivation did not significantly alter the IC₅₀ value for dabrafenib, suggesting that the effects of *SPRED1* loss were only visible upon more complete inhibition of *BRAF*^{V600E} oncogenic activity. This phenotype was specific for *SPRED1* down-regulation, as *SPRED1* overexpression partially restored sensitivity to the drug (Fig. S2 B). Resistance to *BRAF*^{V600E} inhibition was associated with the persistence of a low but detectable level of ERK phosphorylation in dabrafenib-treated cells expressing shRNAs against *SPRED1* (Fig. 2 B and Fig. S2 C). This residual MAPK activity downstream of *SPRED1* down-regulation at least partially explained the observed resistance, since the latter was abrogated by treatment with the MEK inhibitor trametinib (Fig. S2 D). At the molecular level, *SPRED1* down-regulation increased Ras activity both in untreated conditions and under *BRAF*




Figure 1. ***SPRED1* is frequently deleted in human cutaneous melanoma.** (A) Diagram representing copy-number losses in the TCGA cohort of human cutaneous melanomas (363 samples). Frequent deletions of *CDKN2A* on chromosome 9 and *PTEN* on chromosome 10 are highlighted. *SPRED1* was identified by GISTIC analysis in a recurrent focal deletion on chromosome 15. (B) Driver lesions in oncogenes occurring with *SPRED1* alterations in human cutaneous melanoma (total, 363 samples). (C) Survival curves of patients with melanoma stratified according to *SPRED1* expression levels. High *SPRED1*, 88 samples (25%) with highest mRNA expression; low *SPRED1*, 88 samples (25%) with lowest mRNA expression. **, P = 0.0012, log-rank test.

inhibition, as evidenced by higher levels of Ras-GTP (Fig. S2 E), in line with the idea that *SPRED1* modulates the MAPK pathway by inhibiting the activity of wild-type Ras. Interestingly, *SPRED1* protein levels decreased following MAPK pathway inhibition by dabrafenib in *BRAF*^{V600E}-driven human melanoma cells and increased in response to the restoration of MAPK activity after drug washout (Fig. S2 F), suggesting that *SPRED1* itself is regulated by the output of the pathway. *SPRED1* thus acts as a negative feedback regulator of the MAPK pathway. The effect of long-term treatment with dabrafenib on the colony-forming capacity (Fig. 2, C and D) and growth of melanoma cells (Fig. 2, E and F) was also significantly reduced by *SPRED1* down-regulation. Together, these findings demonstrate that *SPRED1* loss decreases the sensitivity of *BRAF*-driven melanoma cells to *BRAF* inhibition by sustaining partial MAPK pathway activity.

***SPRED1* loss is selected for in human melanoma cells under continuous *BRAF* inhibition**

We confirmed these results with a CRISPR approach using vectors expressing Cas9 and three independent guide RNAs (gRNAs) targeting *SPRED1*. We suboptimally transfected *BRAF*-driven A375 cells to mimic the effects of mosaic acquisition of *SPRED1* loss and subjected them to long-term *BRAF* inhibition. We then assessed the prevalence of *SPRED1* inactivation over-time in these heterogeneous cultures at the genomic level by sequencing of the CRISPR target sites and at the protein level by Western blotting. Dabrafenib treatment dramatically reduced the growth of A375 cells. Yet, we observed the rapid emergence of clones resistant to dabrafenib treatment after one passage, specifically in cultures transfected with *SPRED1* gRNAs (Fig. 3 A). The proportion of *SPRED1* mutant alleles sharply increased in dabrafenib-treated cultures while remaining constant




Figure 2. *SPRED1* down-regulation reduces sensitivity to BRAF inhibition in BRAF-driven human melanoma cell lines by sustaining MAPK activity *in vitro*. (A) Viability of BRAF-driven A375 human melanoma cells stably expressing a control shRNA (shCTRL) or shRNAs directed against *SPRED1*

(shSPRED1#2 and #4) and treated with increasing concentrations of the BRAF^{V600E} inhibitor dabrafenib for 4 d. Mean $\pm$ SD of three independent experiments; *, $P < 0.05$ for both shRNAs against *SPRED1* compared with the control shRNA, paired two-tailed t test. **(B)** Western blot analysis of MAPK pathway activity in the cells described in A treated with dabrafenib (Dab) for 6 h. C, shCTRL; S2, shSPRED1#2; S4, shSPRED1#4. Signal intensity ratio of p-ERK to total ERK is indicated. Note the residual p-ERK levels under strong BRAF inhibition in cells with reduced *SPRED1*. Representative of three independent experiments. **(C)** Representative images of colonies formed in Matrigel by the cells described in A after 14 d of treatment with dabrafenib or DMSO (vehicle). Scale bar, 500 μ m. **(D)** Number of colonies quantified from the experiments described in C, relative to DMSO-treated cells. Mean $\pm$ SD of five independent experiments; **, $P < 0.01$ compared with shCTRL, paired two-tailed t test. **(E)** Representative images of clones formed by the cells described in A after 14 d of treatment with dabrafenib and stained by crystal violet. Scale bar, 2 mm. **(F)** Intensity of crystal violet staining from the experiments described in E relative to DMSO-treated cells. Mean $\pm$ SD of six independent experiments; *, $P < 0.05$; **, $P < 0.01$ compared with shCTRL, paired two-tailed t test.

in vehicle-treated cultures (Fig. 3 B). Deep sequencing revealed that the vast majority of these CRISPR variants exhibited frameshift mutations (Fig. S3, A and B). Accordingly, *SPRED1* protein levels remained constant over five passages in the absence of drugs but dropped within three passages of dabrafenib treatment (Fig. 3 C), indicating that *SPRED1*-deficient cells were rapidly selected for. Within five passages under drug pressure, the genotype of transfected cultures had thus evolved from mostly wild type to almost completely knockout for *SPRED1*. As expected, *SPRED1* knockout cells displayed residual MAPK signaling under dabrafenib treatment compared with control cells (Fig. 3 D). These data show that *SPRED1* loss confers a selective advantage to melanoma cells under continuous pharmacologic BRAF inhibition by increasing cell proliferation and/or survival in vitro.

SPRED1 loss confers resistance to BRAF inhibition in BRAF-driven zebrafish melanoma in vivo

We next assessed the effect of *SPRED1* inactivation on melanoma sensitivity to targeted therapy in vivo. To test the response of primary zebrafish melanoma to pharmacological challenge, we treated adult zebrafish daily for 14 d in a small volume of drugs (Fig. S3 C). Treatment of BRAF-driven melanoma with the BRAF^{V600E} inhibitor dabrafenib abrogated MAPK signaling in tumors (Fig. S3 D). Primary *spred1* CRISPR tumors in zebrafish displayed a reduced response to dabrafenib compared with control tumors after both 7 and 14 d of treatment (Fig. 4, A and B; and Fig. S3 E). These results indicate that *SPRED1* loss also reduces the sensitivity of BRAF-driven melanoma cells to BRAF inhibition in vivo.

SPRED1 deletion is associated with acquired resistance to MAPK inhibition in a patient with melanoma

When human melanoma cell lines and clinical melanoma are exposed to MAPK inhibitors chronically, the resulting acquired resistant cells and tumors often harbor multiple genetic and nongenetic alterations capable of driving the resistance phenotype (Hugo et al., 2015). With combinatorial targeting of the MAPK pathway using BRAF^{V600E} and allosteric MEK inhibitors, multiple genetic alterations often converge to reactivate the MAPK pathway (Moriceau et al., 2015). In the context of the above functional data, we asked whether *SPRED1* loss contributes to acquired resistance clinically by reanalyzing whole-exome sequence data for patient-derived tumors. A patient (patient 11 in Moriceau et al. [2015] and patient 22 in Hugo et al. [2015]) with metastatic BRAF^{V600E} melanoma was treated with dabrafenib plus trametinib. Comparison of whole-exome sequencing

data from a pretreatment tumor (January 2013), three distinct double-drug disease-progressive (DD-DP) tumors (October 2013), and the patient-matched normal genomic DNA detected resistance-associated copy-number loss of a region within chromosome 15 encompassing *SPRED1* in all three DD-DP tumors relative to the pretreatment tumor (Fig. 4 C). This finding is consistent with a key role of MAPK reactivation, which is driven at least in part by *SPRED1* deletion, underlying this patient's disease progression.

During chronic selection with MAPK inhibitors (especially with dual MAPK pathway inhibition), multiple but convergent genetic and nongenetic alterations are likely operative in fully reactivating the MAPK pathway. Accordingly, in the patient presented here, low-level BRAF^{V600E} copy-number gain and *DUSP4* copy-number loss already coexist in all three acquired resistant tumors in addition to the *SPRED1* copy-number loss (Fig. 4 C). It is not known whether these are subclonal and mutually exclusive events, but functional studies indicate that distinct MAPK alterations can cooperate quantitatively (nonredundantly) to achieve a more robust resistant phenotype (Moriceau et al., 2015). *DUSP* and *SPROUTY* family members are both transcriptional targets of phospho-ERK (p-ERK) and negative feedback regulators of the MAPK pathway, albeit at distinct steps of the signaling cascade (Pratilis et al., 2009). Mechanistically, it is conceivable that recurrent drivers of MAPK inhibitor resistance (e.g., BRAF amplification and NRAS mutations) render BRAF^{V600E} signaling in resistant tumor cells more sensitive to negative feedback regulation. Therefore, there would be selective pressure to coacquire alterations that disable negative feedback at multiple levels of the MAPK pathway.

Collectively, our results demonstrate that deletions of the negative MAPK pathway regulator *SPRED1* confer resistance to MAPK inhibition in mutant BRAF-driven melanoma in human cell lines, animal models, and patients. We found loss-of-function alterations of *SPRED1* through deep deletions or truncating mutations in 4% of melanomas. In the context of BRAF^{V600E}, *SPRED1* loss modestly affected melanoma initiation in vivo or melanoma growth in the absence of treatment in vitro. While this may explain the relatively low frequency of *SPRED1* deletions in human cutaneous melanoma, it also contrasts with our observations in KIT-driven melanoma, where *SPRED1* inactivation significantly accelerated tumor onset and increased cell proliferation (Ablain et al., 2018). This difference may be due to the position at which *SPRED1* exerts its tumor-suppressor activity in the MAPK pathway. Consistent with our data showing that




Figure 3. *SPRED1* loss is selected for in human melanoma cells under continuous BRAF inhibition. (A) Representative pictures at indicated passages (P) of cultures of BRAF-driven A375 human melanoma cells transiently transfected with a vector expressing Cas9 and either a control gRNA or a gRNA targeting *SPRED1* and treated with DMSO (vehicle) or 100 nM dabrafenib (Dab). Scale bar, 100 μ m. **(B)** Evolution of frameshift variant allele fraction in cultured A375 human melanoma cells transiently transfected with two independent vectors targeting *SPRED1* by CRISPR and treated with either DMSO or 100 nM dabrafenib over five passages. Representative of three independent experiments. **(C)** Western blot analysis of *SPRED1* levels in the cultures described in B. Representative of three independent experiments. **(D)** Western blot analysis of MAPK pathway activity in A375 human melanoma cells transiently transfected with three independent vectors targeting *SPRED1* by CRISPR and stimulated with 0, 10, 30, or 100 nM dabrafenib before any treatment (P0) or after five passages in 100 nM dabrafenib (P5). Representative of three independent experiments.




Figure 4. **SPRED1 loss confers resistance to BRAF inhibition in BRAF-driven zebrafish melanoma in vivo and is associated with acquired resistance to targeted therapy in a patient with melanoma.** (A) Representative pictures of zebrafish bearing *BRAF/tp53* or *BRAF/tp53/spred1* tumors and treated daily with 5 μ M dabrafenib for 14 d. Scale bar, 1 cm. (B) Quantification of tumor size after 14 d of dabrafenib treatment relative to tumor size before treatment in zebrafish with *BRAF/tp53* ($n = 13$) or *BRAF/tp53/spred1* ($n = 9$) tumors. Pooled data of three independent experiments. **, $P = 0.01$, two-tailed t test. (C) Circos representation of chromosome 15 copy-number changes of four tumors from a patient who was treated with and responded to dabrafenib plus trametinib. The outermost layer represents the chromosomal regions of chromosome 15, and the inner heatmaps indicate copy-number changes (log2 ratio) averaged in 1-kb genomic windows (from inner to outer: baseline, DD-DP1, DD-DP2, and DD-DP3). Arrow indicates the location of *SPRED1*.

SPRED1 loss enhances Ras activity in melanoma cells, previous reports have indicated that *SPRED1* directly represses Ras, thus acting downstream of KIT but upstream of RAF (Stowe et al., 2012). *SPRED1* loss may therefore strongly potentiate the MAPK signal induced by KIT activation that transits through wild-type Ras, while its effect on MEK and ERK phosphorylation levels is masked in the context of *BRAF*^{V600E} that bypasses wild-type Ras and directly activates MEK (Fig. S3 F). Combined with the fact that *SPRED1* is likely a weaker MAPK regulator than *BRAF*^{V600E}, this may also explain why the effects of *SPRED1* loss of function on melanoma cell proliferation are only visible upon profound inhibition of mutant *BRAF* (i.e., under relatively high dabrafenib concentrations). Upon *BRAF* inhibition, melanoma cells may rely on basal MAPK signaling for survival. Under these circumstances, we showed that *SPRED1* loss by itself increases residual MAPK activity and sustains low levels of cell proliferation, thus allowing melanoma cells to resist treatment acutely (Fig. S3 F). Our findings uncover *SPRED1* as one of the feedback mechanisms that are altered in melanoma and whose loss confers resistance to MAPK inhibition.

Materials and methods

DNA constructs

To down-regulate *SPRED1* in human melanoma cell lines, we used pLKO shRNA lentiviral vectors (Sigma-Aldrich) with the following hairpin sequences: shSPRED1#2, 5'-CCGGGAGCATGT TGTATCATTTGTATCTCGAGATACAATGATACAACATGCTCTT TTTG-3' (TRCN0000056712); shSPRED1#4, 5'-CCGGGAATACGT ACAGCGGCAAATACTCGAGTATTTGCCGCTGTACGTATTCTT TTTTG-3' (TRCN0000417109).

To inactivate *SPRED1* in human melanoma cell lines, we used the LentiCRISPR lentiviral vector (Shalem et al., 2014) with the following gRNAs: SPRED1#1, 5'-GCGGTGAGGGAAAGATGAGCG-3'; SPRED1#2, 5'-GGTGGATGGTTACCACTTGG-3'; SPRED1#3, 5'-GTG GTTACCACTTGGAGGGAG-3'.

To inactivate *spred1* in zebrafish melanomas, we used the CRISPR MiniCoopR vector (Ablain et al., 2018) that targets genes specifically in the melanocytes of the zebrafish. The following gRNAs were introduced into the CRISPR MiniCoopR vector by restriction cloning using the BseRI enzyme: *tp53*, 5'-GGTGGG AGAGTGGATGGCTG-3'; *cdkn2a*, 5'-GTTCTGGCAGCGTCGTGC AG-3'; *spred1*, 5'-GGCGTCCGCCGGCTCTGGA-3'.

Zebrafish handling

Zebrafish were handled according to our vertebrate animal protocol that has been approved by Boston Children's Hospital Animal Care Committee and includes detailed experimental procedures for all in vivo experiments described in this paper. Zebrafish of *casper* strain were bred and embryos were collected for microinjection. The Tol2 transgenesis technology enables the stable integration of expression vectors into the fish genome (Kawakami et al., 2004). 25 pg of DNA constructs and 25 pg of Tol2 mRNA were injected into one cell-stage embryos. After microinjection, embryos were raised in E3 medium at 28.5°C.

Embryos were sorted for melanocyte rescue at 96 h after fertilization and raised to adulthood (20–25 zebrafish per 3.5-liter tank). Adult fish were scored weekly for melanoma formation starting at the first appearance of raised lesions. Tumor scoring in adult zebrafish was blinded by deidentifying each tank for the duration of the experiment and only revealing the genotype of each tank at the time of final analysis. Experiments were independently repeated at least three times. Statistical analysis on Kaplan–Meier survival curves was performed using log-rank (Mantel–Cox) test.

Adult fish treatment

Adult zebrafish were treated daily by overnight (12 h) immersion in 50 ml of water containing the drug in Petri dishes. Treatment was performed with DMSO or 5 µM dabrafenib (LC Laboratories) for 14 d. The concentration of dabrafenib was determined by a dose-escalation study starting at 100 nM dabrafenib to identify the maximum tolerated dose in adult zebrafish bearing primary melanomas.

Adult fish were photographed using a Nikon D3100 camera with an AF-S Micro NIKKOR 60-mm lens. Tumor size was measured with ImageJ.

TCGA data analysis

SPRED1 was identified in a frequent focal deletion by GISTIC analysis of the TCGA data for human melanoma (Beroukhi et al., 2007). We focused our analysis on a cohort of 363 patients with both copy-number and mutation information. The various alterations in select genes were examined using OncoPrint (Cerami et al., 2012; Gao et al., 2013). Survival data were available for 352 patients.

Cell culture

A375 and UACC257 cell lines were purchased from ATCC and cultured in DMEM (Life Technologies), 10% FBS (Atlanta Biologicals), 1X GlutaMAX (Life Technologies), and 1% penicillin-streptomycin (Life Technologies). Cells were grown at 37°C in 5% CO₂. All cultures were regularly checked for the presence of mycoplasma.

Lentiviral particles were produced by cotransfection of 293T cells with pLKO or pHAGE vectors and packaging plasmids pVSV-G and psPAX2 using FuGENE HD (Promega). Viral particles were harvested 48 and 72 h after transfection, concentrated by overnight polyethylene glycol precipitation, resuspended in PBS, and stored at –80°C. Human melanoma cell lines were overlaid with viral particles diluted in medium supplemented with 5 µg/ml

polybrene (Sigma-Aldrich) for 12 h at 37°C. 48 h after transduction, infected cells were selected with 1 µg/ml puromycin (Gibco) and maintained under selection by replacing the antibiotics every 48 h.

A375 cells were transfected with pLenti-CRISPR vectors using FuGENE HD (Promega).

Proliferation and drug sensitivity were measured using the CellTiter Glo (Promega) luminescent cell viability assay, according to the manufacturer's instructions. Cells were seeded at an initial density of 1,000 cells/well (for A375 cell line) or 3,000 cells/well (for UACC257 cell line) in 394-well plates in duplicate or triplicate wells. Experiments were repeated at least three times independently, and a paired two-tailed *t* test was used to assess significance between groups.

To measure cell growth under long-term drug treatment, A375 cells were plated at a density of 300 cells/well in 24-well plates. Medium containing DMSO or dabrafenib was replaced every 2 d. After 14 d of treatment, cells were fixed with ice-cold methanol for 10 min, stained with a 0.5% crystal violet solution for 10 min, washed with water, and imaged using a Nikon SMZ18 microscope equipped with a DS-Ri2 camera. Staining intensity in each well was quantified with ImageJ.

To measure colony-forming capacity, cells were seeded at a density of 2,000 cells/well in 50% Matrigel containing DMSO or dabrafenib in 24-well plates. The semisolid medium (400 µl) was covered with 1 ml of DMEM and 10% FBS containing DMSO or dabrafenib that was replaced every 2 d. After 14 d, wells were imaged using a Nikon SMZ18 microscope equipped with a DS-Ri2 camera. The number of colonies in each well was quantified with ImageJ.

CRISPR sequencing

Genomic DNA from human cell lines or zebrafish tumors was extracted with QuickExtract solution (Epibio). DNA libraries were prepared by PCR amplification of the CRISPR loci using the following primers: *tp53*, 5'-CTGTGTTTCCAGGAGTACTTG-3' and 5'-TATGTGTGTATGCGCTTTTG-3'; *cdkn2a*, 5'-ATCATGACGTTACTGGCGTTTA-3' and 5'-TCGCAGTGATCTTTTGTATTG-3'; *spred1*, 5'-GAGAGTGTGTGATCTGTGGCTC-3' and 5'-CATTCGCTAATGTTTTATGCCA-3'.

Sequencing was performed by the MGH DNA core and analyzed using the Basepair online tool (<https://www.basepairtech.com>).

Protein analysis

For Western blot, cells were lysed with RIPA lysis buffer containing protease inhibitors (cOmplete; Roche) and phosphatase inhibitors (PhosSTOP; Roche). Lysates were incubated for 20 min on ice and spun down for 10 min at 14,000 revolutions per minute at 4°C. Protein concentrations were normalized using the DC protein assay (Bio-Rad). Samples were denatured by adding Laemmli sample buffer (Bio-Rad) with 5% β-mercaptoethanol (Sigma-Aldrich) and boiled at 95°C for 5 min before loading. Proteins were separated on a 12% mini-PROTEAN TGX (Bio-Rad) precast gel and transferred onto a polyvinylidene fluoride membrane using the iBlot2 system (Thermo Fisher Scientific). The primary antibodies were SPRED1 (#94063; Cell Signaling

Technologies), p-ERK (#9101; Cell Signaling Technologies), ERK (#9102; Cell Signaling Technologies), and β -ACTIN (A2228; Sigma-Aldrich). Secondary antibodies were HRP anti-mouse and HRP anti-rabbit (Cell Signaling Technologies). Membranes were developed using Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific). Ras activity was measured by purifying GTP-bound Ras from cell lysates using Ras Activation Assay Biochem Kit (BK008; Cytoskeleton) and following the manufacturer's instructions. Band intensity was quantified with ImageJ.

Copy-number variation analysis

Whole-exome sequence data of patient-derived tumors ($n = 4$) along with normal tissues of a melanoma patient were analyzed to detect the somatic copy-number variations as previously described (Moriceau et al., 2015). Circos representation of copy-number changes was generated by R package RCircos. Melanoma tissues and patient-matched normal tissue were collected with the approval of institutional review boards at University of California, Los Angeles and informed consent of the patient.

Statistical analysis

Comparison of Kaplan–Meier survival curves was performed by a log-rank (Mantel–Cox) test. Statistical differences in cell viability experiments were estimated using paired two-tailed t test. Graphs show the mean $\pm$ SD. No statistical methods were used to predetermine sample size. *, $P < 0.05$; **, $P < 0.01$; n.s., not significant ($P > 0.05$).

Online supplemental material

Fig. S1 shows that *SPRED1* inactivation modestly alters melanoma growth in vitro and in vivo. Fig. S2 demonstrates that *SPRED1* inactivation confers resistance to BRAF inhibition in BRAF-driven human melanoma cell lines by sustaining MAPK pathway activity. Fig. S3 describes the influence of *SPRED1* inactivation on the sensitivity of zebrafish melanomas to long-term BRAF inhibition both in vitro and in vivo.

Acknowledgments

This work was supported by the National Institutes of Health/National Cancer Institute (grants R01CA103846 and P01CA163222 to L.I. Zon; grant K99CA201465 to J. Ablain; grants 1R01CA176111A1 and 1R21CA215910-011 to R.S. Lo; and grant P01CA244118 to G. Moriceau and R.S. Lo), the Melanoma Research Alliance (L.I. Zon, S. Liu, and R.S. Lo), and the V Foundation for Cancer Research (R.S. Lo). S. Liu is supported by a Jonsson Comprehensive Cancer Center postdoctoral fellowship and R.S. Lo by the Ressler Family Foundation. L.I. Zon is a Howard Hughes Medical Institute Investigator.

Author contributions: J. Ablain designed the study, performed cell line and zebrafish experiments, performed TCGA data analyses, analyzed results, discussed findings, and wrote the manuscript. S. Liu performed genomic analyses on patients with melanoma treated with MAPK inhibitors, discussed findings, and wrote the manuscript. G. Moriceau generated genomic data from clinical samples and discussed

findings. R.S. Lo collected clinical samples, discussed findings, and wrote the manuscript. L.I. Zon discussed findings and wrote the manuscript.

Disclosures: R.S. Lo reported grants from Pfizer, Merck, OncoSec, and BMS outside the submitted work. L.I. Zon reported personal fees from Scholar Rock Inc., Fate Therapeutics, CAMP4 Therapeutics, Amagma Therapeutics, Celularity, and Cellarity outside the submitted work. No other disclosures were reported.

Submitted: 28 May 2020

Revised: 12 October 2020

Accepted: 6 November 2020

References

- Ablain, J., E.M. Durand, S. Yang, Y. Zhou, and L.I. Zon. 2015. A CRISPR/Cas9 vector system for tissue-specific gene disruption in zebrafish. *Dev. Cell.* 32:756–764. <https://doi.org/10.1016/j.devcel.2015.01.032>
- Ablain, J., M. Xu, H. Rothschild, R.C. Jordan, J.K. Mito, B.H. Daniels, C.F. Bell, N.M. Joseph, H. Wu, B.C. Bastian, et al. 2018. Human tumor genomics and zebrafish modeling identify *SPRED1* loss as a driver of mucosal melanoma. *Science*. 362:1055–1060. <https://doi.org/10.1126/science.aau6509>
- Akbani, R., K.C. Akdemir, B.A. Aksoy, M. Albert, A. Ally, S.B. Amin, H. Arachchi, A. Arora, J.T. Auman, B. Ayala, et al. Cancer Genome Atlas Network. 2015. Genomic Classification of Cutaneous Melanoma. *Cell*. 161:1681–1696. <https://doi.org/10.1016/j.cell.2015.05.044>
- Alexandrov, L.B., S. Nik-Zainal, D.C. Wedge, S.A.J.R. Aparicio, S. Behjati, A.V. Biankin, G.R. Bignell, N. Bolli, A. Borg, A.L. Børresen-Dale, et al. ICGC PedBrain. 2013. Signatures of mutational processes in human cancer. *Nature*. 500:415–421. <https://doi.org/10.1038/nature12477>
- Ballester, R., D. Marchuk, M. Boguski, A. Saulino, R. Letcher, M. Wigler, and F. Collins. 1990. The NFI locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. *Cell*. 63:851–859. [https://doi.org/10.1016/0092-8674\(90\)90151-4](https://doi.org/10.1016/0092-8674(90)90151-4)
- Beroukhim, R., G. Getz, L. Nghiemphu, J. Barretina, T. Hsueh, D. Linhart, I. Vivanco, J.C. Lee, J.H. Huang, S. Alexander, et al. 2007. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. *Proc. Natl. Acad. Sci. USA*. 104:20007–20012. <https://doi.org/10.1073/pnas.0710052104>
- Bollag, G., P. Hirth, J. Tsai, J. Zhang, P.N. Ibrahim, H. Cho, W. Spevak, C. Zhang, Y. Zhang, G. Habets, et al. 2010. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. *Nature*. 467:596–599. <https://doi.org/10.1038/nature09454>
- Brems, H., M. Chmara, M. Sahbatou, E. Denayer, K. Taniguchi, R. Kato, R. Somers, L. Messiaen, S. De Schepper, J.P. Fryns, et al. 2007. Germline loss-of-function mutations in *SPRED1* cause a neurofibromatosis 1-like phenotype. *Nat. Genet.* 39:1120–1126. <https://doi.org/10.1038/ng2113>
- Ceol, C.J., Y. Houvras, J. Jane-Valbuena, S. Bilodeau, D.A. Orlando, V. Battisti, L. Fritsch, W.M. Lin, T.J. Hollmann, F. Ferré, et al. 2011. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. *Nature*. 471:513–517. <https://doi.org/10.1038/nature09806>
- Cerami, E., J. Gao, U. Dogrusoz, B.E. Gross, S.O. Sumer, B.A. Aksoy, A. Jacobsen, C.J. Byrne, M.L. Heuer, E. Larsson, et al. 2012. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2:401–404. <https://doi.org/10.1158/2159-8290.CD-12-0095>
- Chapman, P.B., A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, et al. BRIM-3 Study Group. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N. Engl. J. Med.* 364:2507–2516. <https://doi.org/10.1056/NEJMoa1103782>
- Flaherty, K.T., I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, J.A. Sosman, P.J. O'Dwyer, R.J. Lee, J.F. Grippo, K. Nolop, and P.B. Chapman. 2010. Inhibition of mutated, activated BRAF in metastatic melanoma. *N. Engl. J. Med.* 363:809–819. <https://doi.org/10.1056/NEJMoa1002011>
- Gao, J., B.A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, S.O. Sumer, Y. Sun, A. Jacobsen, R. Sinha, E. Larsson, et al. 2013. Integrative analysis of

- complex cancer genomics and clinical profiles using the cBioPortal. *Sci. Signal.* 6:pl1. <https://doi.org/10.1126/scisignal.2004088>
- Hauschild, A., J.J. Grob, L.V. Demidov, T. Jouary, R. Gutzmer, M. Millward, P. Rutkowski, C.U. Blank, W.H. Miller Jr., E. Kaempgen, et al. 2012. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *Lancet.* 380:358–365. [https://doi.org/10.1016/S0140-6736\(12\)60868-X](https://doi.org/10.1016/S0140-6736(12)60868-X)
- Hayward, N.K., J.S. Wilmott, N. Waddell, P.A. Johansson, M.A. Field, K. Nones, A.M. Patch, H. Kakavand, L.B. Alexandrov, H. Burke, et al. 2017. Whole-genome landscapes of major melanoma subtypes. *Nature.* 545: 175–180. <https://doi.org/10.1038/nature22071>
- Hirata, Y., H. Brems, M. Suzuki, M. Kanamori, M. Okada, R. Morita, I. Llano-Rivas, T. Ose, L. Messiaen, E. Legius, and A. Yoshimura. 2016. Interaction between a domain of the negative regulator of the ras-ERK pathway, SPRED1 protein, and the GTPase-activating protein-related domain of neurofibromin is implicated in legius syndrome and neurofibromatosis type 1. *J. Biol. Chem.* 291:3124–3134. <https://doi.org/10.1074/jbc.M115.703710>
- Hugo, W., H. Shi, L. Sun, M. Piva, C. Song, X. Kong, G. Moriceau, A. Hong, K.B. Dahlman, D.B. Johnson, et al. 2015. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. *Cell.* 162: 1271–1285. <https://doi.org/10.1016/j.cell.2015.07.061>
- Johannessen, C.M., J.S. Boehm, S.Y. Kim, S.R. Thomas, L. Wardwell, L.A. Johnson, C.M. Emery, N. Stransky, A.P. Cogdill, J. Barretina, et al. 2010. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. *Nature.* 468:968–972. <https://doi.org/10.1038/nature09627>
- Kawakami, K., H. Takeda, N. Kawakami, M. Kobayashi, N. Matsuda, and M. Mishina. 2004. A transposon-mediated gene trap approach identifies developmentally regulated genes in zebrafish. *Dev. Cell.* 7:133–144. <https://doi.org/10.1016/j.devcel.2004.06.005>
- Maertens, O., B. Johnson, P. Hollstein, D.T. Frederick, Z.A. Cooper, L. Messiaen, R.T. Bronson, M. McMahon, S. Granter, K. Flaherty, et al. 2013. Elucidating distinct roles for NF1 in melanomagenesis. *Cancer Discov.* 3: 338–349. <https://doi.org/10.1158/2159-8290.CD-12-0313>
- Martin, G.A., D. Viskochil, G. Bollag, P.C. McCabe, W.J. Crosier, H. Haubruck, L. Conroy, R. Clark, P. O'Connell, R.M. Cawthon, et al. 1990. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. *Cell.* 63:843–849. [https://doi.org/10.1016/0092-8674\(90\)90150-D](https://doi.org/10.1016/0092-8674(90)90150-D)
- McArthur, G.A., P.B. Chapman, C. Robert, J. Larkin, J.B. Haanen, R. Dummer, A. Ribas, D. Hogg, O. Hamid, P.A. Ascierto, et al. 2014. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. *Lancet Oncol.* 15:323–332. [https://doi.org/10.1016/S1470-2045\(14\)70012-9](https://doi.org/10.1016/S1470-2045(14)70012-9)
- McLendon, R., A. Friedman, D. Bigner, E.G. Van Meir, D.J. Brat, G.M. Mastrogiannis, J.J. Olson, T. Mikkelsen, N. Lehman, K. Aldape, et al. Cancer Genome Atlas Research Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature.* 455:1061–1068. <https://doi.org/10.1038/nature07385>
- Moriceau, G., W. Hugo, A. Hong, H. Shi, X. Kong, C.C. Yu, R.C. Koya, A.A. Samatar, N. Khanlou, J. Braun, et al. 2015. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. *Cancer Cell.* 27: 240–256. <https://doi.org/10.1016/j.ccell.2014.11.018>
- Nazarian, R., H. Shi, Q. Wang, X. Kong, R.C. Koya, H. Lee, Z. Chen, M.K. Lee, N. Attar, H. Sazegar, et al. 2010. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. *Nature.* 468: 973–977. <https://doi.org/10.1038/nature09626>
- Nonami, A., R. Kato, K. Taniguchi, D. Yoshiga, T. Taketomi, S. Fukuyama, M. Harada, A. Sasaki, and A. Yoshimura. 2004. Spred-1 negatively regulates interleukin-3-mediated ERK/mitogen-activated protein (MAP) kinase activation in hematopoietic cells. *J. Biol. Chem.* 279:52543–52551. <https://doi.org/10.1074/jbc.M405189200>
- Pratils, C.A., B.S. Taylor, Q. Ye, A. Viale, C. Sander, D.B. Solit, and N. Rosen. 2009. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. *Proc. Natl. Acad. Sci. USA.* 106:4519–4524. <https://doi.org/10.1073/pnas.0900780106>
- Shalem, O., N.E. Sanjana, E. Hartenian, X. Shi, D.A. Scott, T. Mikkelsen, D. Heckl, B.L. Ebert, D.E. Root, J.G. Doench, and F. Zhang. 2014. Genome-scale CRISPR-Cas9 knockout screening in human cells. *Science.* 343: 84–87. <https://doi.org/10.1126/science.1247005>
- Shi, H., G. Moriceau, X. Kong, M.K. Lee, H. Lee, R.C. Koya, C. Ng, T. Chodon, R.A. Scolyer, K.B. Dahlman, et al. 2012. Melanoma whole-exome sequencing identifies (V600E)BRAF amplification-mediated acquired B-RAF inhibitor resistance. *Nat. Commun.* 3:724. <https://doi.org/10.1038/ncomms1727>
- Stowe, I.B., E.L. Mercado, T.R. Stowe, E.L. Bell, J.A. Osés-Prieto, H. Hernández, A.L. Burlingame, and F. McCormick. 2012. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. *Genes Dev.* 26:1421–1426. <https://doi.org/10.1101/gad.190876.112>
- Wagle, N., C. Emery, M.F. Berger, M.J. Davis, A. Sawyer, P. Pochanard, S.M. Kehoe, C.M. Johannessen, L.E. Macconail, W.C. Hahn, et al. 2011. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. *J. Clin. Oncol.* 29:3085–3096. <https://doi.org/10.1200/JCO.2010.33.2312>
- Wakioka, T., A. Sasaki, R. Kato, T. Shouda, A. Matsumoto, K. Miyoshi, M. Tsuneoka, S. Komiya, R. Baron, and A. Yoshimura. 2001. Spred is a Sprouty-related suppressor of Ras signalling. *Nature.* 412:647–651. <https://doi.org/10.1038/35088082>
- Whittaker, S.R., J.P. Theurillat, E. Van Allen, N. Wagle, J. Hsiao, G.S. Cowley, D. Schadendorf, D.E. Root, and L.A. Garraway. 2013. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. *Cancer Discov.* 3:350–362. <https://doi.org/10.1158/2159-8290.CD-12-0470>
- Xu, G.F., B. Lin, K. Tanaka, D. Dunn, D. Wood, R. Gesteland, R. White, R. Weiss, and F. Tamanoi. 1990a. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of *S. cerevisiae*. *Cell.* 63:835–841. [https://doi.org/10.1016/0092-8674\(90\)90149-9](https://doi.org/10.1016/0092-8674(90)90149-9)
- Xu, G.F., P. O'Connell, D. Viskochil, R. Cawthon, M. Robertson, M. Culver, D. Dunn, J. Stevens, R. Gesteland, R. White, and R. Weiss. 1990b. The neurofibromatosis type 1 gene encodes a protein related to GAP. *Cell.* 62: 599–608. [https://doi.org/10.1016/0092-8674\(90\)90024-9](https://doi.org/10.1016/0092-8674(90)90024-9)
- Yan, W., E. Markegard, S. Dharmiaiah, A. Urisman, M. Drew, D. Esposito, K. Scheffzek, D.V. Nissley, F. McCormick, and D.K. Simanshu. 2020. Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Oncogenic EGFR. *Cell Rep.* 32:107909. <https://doi.org/10.1016/j.celrep.2020.107909>
- Yao, Z., R. Yaeger, V.S. Rodrik-Outmezguine, A. Tao, N.M. Torres, M.T. Chang, M. Drosten, H. Zhao, F. Cecchi, T. Hembrough, et al. 2017. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. *Nature.* 548:234–238. <https://doi.org/10.1038/nature23291>

Supplemental material




Figure S1. ***SPRED1* inactivation modestly alters melanoma growth in vitro and in vivo.** (A) Driver lesions in tumor-suppressor genes occurring with *SPRED1* alterations in human cutaneous melanoma (total, 363 samples). (B) Western blot analysis of *SPRED1* levels in A375 melanoma cells stably transduced with shRNAs directed against *SPRED1*. shRNA#2 and #4 were selected for *SPRED1* down-regulation experiments. Representative of two independent experiments. (C) Proliferation of *BRAF*-driven A375 human melanoma cells expressing either a control shRNA (shCTRL) or shRNAs against *SPRED1* (shSPRED1#2 and #4). Mean $\pm$ SD of five independent experiments. $P > 0.05$ (not significant) compared with shCTRL, paired two-tailed t test. (D) Tumor-free survival curves of *casper* zebrafish injected with vectors expressing *BRAF*^{V600E} and targeting either *tp53* or both *tp53* and *spred1*. Pooled data of three independent experiments. $P = 0.08$ (n.s., not significant), log-rank test. (E) Proportion of *spred1* mutant alleles in 10 primary *BRAF/tp53/spred1* zebrafish melanomas, as measured by deep sequencing of the CRISPR target loci. Indels are indicated as the number of base pairs altered followed by the type of indel: insertion (I) or deletion (D). (F) Tumor-free survival curves of *casper* zebrafish injected with vectors expressing *BRAF*^{V600E} and targeting either *cdkn2a* or both *cdkn2a* and *spred1*. Pooled data of three independent experiments. **, $P = 0.001$, log-rank test.




Figure S2. **SPRED1 inactivation confers resistance to BRAF inhibition in BRAF-driven human melanoma cell lines.** (A) Viability of BRAF-driven UACC257 human melanoma cells stably expressing a control shRNA (shCTRL) or shRNAs directed against *SPRED1* (shSPRED1#2 and #4) and treated with increasing concentrations of the *BRAF^{V600E}* inhibitor dabrafenib for 4 d. Mean $\pm$ SD of three independent experiments; *, $P < 0.05$ for both shRNAs against *SPRED1* compared with the control shRNA, paired t test. (B) Relative viability at 270 nM dabrafenib between A375 cells expressing shRNAs against *SPRED1* (shSPRED1#2 and #4) and cells expressing a control shRNA in the presence (+SPRED1) or absence (-SPRED1) of inducible *SPRED1* expression. Mean $\pm$ SD of four independent experiments. shSPRED1#2: *, $P = 0.03$; shSPRED1#4: *, $P = 0.01$, paired t test. (C) Western blot analysis of MAPK pathway activity in the cells described in A treated with the indicated concentrations of dabrafenib (Dab) for 6 h. C, shCTRL; S2, shSPRED1#2; S4, shSPRED1#4. Representative of three independent experiments. (D) Viability of the cells described in A treated with increasing concentrations of the MEK inhibitor trametinib for 4 d. Mean $\pm$ SD of three independent experiments; $P > 0.05$ (not significant), paired t test. (E) Western blot analysis of SPRED1, active Ras (Ras-GTP) and total Ras levels in BRAF-driven A375 human melanoma cells stably expressing a control shRNA (C) or shRNAs directed against *SPRED1* (S2 and S4) and treated with the indicated concentrations of dabrafenib for 6 h. Signal intensity ratio of Ras-GTP to total Ras is indicated. Representative of two independent experiments. (F) Western blot analysis of MAPK pathway activity and SPRED1 levels in BRAF-driven A375 human melanoma cells treated with 100 nM dabrafenib (+dab) for the indicated durations before drug washout and further culture in the absence of treatment (-dab) for the indicated durations. Representative of three independent experiments.




Figure S3. In vivo treatment of zebrafish melanomas reveals different sensitivities to BRAF inhibition between *BRAF/tp53* and *BRAF/tp53/spred1* tumors. (A) Distribution of *SPRED1* mutant alleles in cultures of BRAF-driven A375 human melanoma cells transiently transfected with a vector expressing Cas9 and either of three gRNAs targeting *SPRED1* after five passages in 100 nM dabrafenib, as measured by deep sequencing of the CRISPR target loci. Indels are indicated as the number of base pairs altered followed by the type of indel: insertion (I) or deletion (D). (B) Most common mutant alleles found in the cells described in A. (C) Schematic representation of the procedure to treat adult zebrafish bearing primary tumors. Fish were immersed in 50 ml water containing the drug for 12 h (overnight). Treatment was repeated daily for 14 d. *ts*, tumor suppressor. (D) Western blot analysis of MAPK pathway activity in primary zebrafish tumors treated with DMSO (control) or 5 μ M dabrafenib for 3 d following the protocol described in C. BRAF, *BRAF^{V600E}*. Representative of two independent experiments. (E) Quantification of tumor size after 7 d of dabrafenib treatment relative to tumor size before treatment in zebrafish bearing *BRAF/tp53* ($n = 13$) or *BRAF/tp53/spred1* ($n = 9$) tumors. Pooled data of three independent experiments. *, $P = 0.03$, two-tailed t test. (F) Diagram summarizing the effect of *SPRED1* loss in BRAF-driven melanoma. Under treatment with the *BRAF^{V600E}* inhibitor dabrafenib, *SPRED1* loss annihilates the inhibitory activity of NF1 on Ras, which results in the activation of the RAF/MEK/ERK cascade that fuels cell survival and proliferation.